Although both ECG and EGCG can potentially inhibit the proliferation and induce apoptosis of cancer cells, EGCG is reportedly the most promising and is under clinical investigation in chemoprevention trials.34 Our results also indicated that EGCG inhibited the PARP16 activity more effectively than ECG, although the binding affinity between EGCG and PARP16 was weaker than the affinity between ECG and PARP16 (Figure 3). This evidence concerns the gene PARP16 and cancer.